0001193125-20-314855.txt : 20201210 0001193125-20-314855.hdr.sgml : 20201210 20201210160553 ACCESSION NUMBER: 0001193125-20-314855 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20201210 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20201210 DATE AS OF CHANGE: 20201210 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Zymeworks Inc. CENTRAL INDEX KEY: 0001403752 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38068 FILM NUMBER: 201380612 BUSINESS ADDRESS: STREET 1: 540-1385 WEST 8TH AVENUE CITY: Vancouver STATE: A1 ZIP: V6H 3V9 BUSINESS PHONE: (604) 678-1388 MAIL ADDRESS: STREET 1: 540-1385 WEST 8TH AVENUE CITY: Vancouver STATE: A1 ZIP: V6H 3V9 FORMER COMPANY: FORMER CONFORMED NAME: Zymeworks Inc DATE OF NAME CHANGE: 20070620 8-K 1 d75372d8k.htm 8-K 8-K
false 0001403752 0001403752 2020-12-10 2020-12-10

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): December 10, 2020

 

 

Zymeworks Inc.

(Exact name of registrant as specified in its charter)

 

 

 

British Columbia, Canada   001-38068   98-1398788

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

 

Suite 540, 1385 West 8th Avenue, Vancouver, British Columbia, Canada   V6H 3V9
(Address of principal executive offices)   (Zip Code)

(604) 678-1388

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading

Symbol(s)

  

Name of each exchange

on which registered

Common Shares, no par value per share   ZYME   New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☐

 

 

 

ITEM 7.01

REGULATION FD DISCLOSURE

On December 10, 2020, Zymeworks Inc. (“Zymeworks”) issued a press release announcing the selection of three abstracts for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually on January 15 – 17, 2021.

On December 10, 2020, Zymeworks filed this press release with the Canadian securities regulatory authorities in Canada on the System for Electronic Document Analysis and Retrieval (“SEDAR”) at www.sedar.com. A copy of this press release is attached as Exhibit 99.1 hereto.

The information provided under this Item (including Exhibit 99.1, attached hereto) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

ITEM 9.01

FINANCIAL STATEMENTS AND EXHIBITS

(d) Exhibits

 

Exhibit
No.

   

Description

99.1    Press Release dated December 10, 2020.
104    Cover Page Interactive Data File (embedded as Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

   

ZYMEWORKS INC.

    (Registrant)
Date: December 10, 2020     By:  

/s/ Neil A. Klompas

    Name:   Neil A. Klompas
    Title:  

Executive Vice President, Business

Operations and Chief Financial Officer

 EX-99.1 2 d75372dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Zanidatamab Clinical Data Selected for Oral Presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium

Vancouver, Canada (December 10, 2020) – Zymeworks Inc. (NYSE: ZYME), a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, today announced the selection of three abstracts for presentation at the American Society of Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium, taking place virtually on January 15 – 17, 2021.

The presentations highlight updated clinical data for the HER2-targeted bispecific antibody, zanidatamab, in HER2-expressing gastroesophageal adenocarcinoma (both as monotherapy and in combination with chemotherapy) and in HER2-expressing/amplified biliary tract cancer (as monotherapy). Zymeworks is currently recruiting globally in a pivotal clinical trial in patients with HER2-amplified biliary tract cancer for which a “trial in progress” poster will also be presented during the meeting.

Oral Presentation Session

Title: Zanidatamab (ZW25) in HER2-expressing gastroesophageal adenocarcinoma (GEA):

Results from a phase I study

Lead Author: Funda Meric-Bernstam, MD, UT MD Anderson Cancer Center, TX

Abstract: 164

Rapid Abstract Session: Esophageal and Gastric Cancer

Date and Time: January 15, 2021 at 11:30 am - 12:15 pm ET

Poster Presentations

The poster presentations will be available on Friday, January 15 at 8:00 am ET on the conference website as well as the Zymeworks website.

Title: Zanidatamab (ZW25) in HER2-positive biliary tract cancers (BTCs): Results from a phase I study.

Lead Author: Funda Meric-Bernstam, MD, UT MD Anderson Cancer Center, TX

Abstract: 299

Poster Session: Hepatobiliary Cancer

Title: A phase IIb, open-label, single-arm study of zanidatamab (ZW25) monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers (BTCs).

Lead Author: Shubham Pant, MD, UT MD Anderson Cancer Center, TX

Abstract: TPS352

Trials in Progress Poster Session: Hepatobiliary Cancer

About Zanidatamab

Zanidatamab is a bispecific antibody, based on Zymeworks’ Azymetric™ platform, that can simultaneously bind two non-overlapping epitopes of HER2, known as biparatopic binding. This unique design results in multiple mechanisms of action including dual HER2 signal blockade,

increased binding, and removal of HER2 protein from the cell surface, and potent effector function leading to encouraging antitumor activity in patients. Zymeworks is developing zanidatamab in multiple Phase 1, Phase 2, and registration-enabling clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. The FDA has granted Breakthrough Therapy designation for zanidatamab in patients with previously treated HER2 gene-amplified biliary tract cancer (BTC), and two Fast Track designations to zanidatamab, one as monotherapy for refractory BTC and one in combination with standard of care chemotherapy for first-line gastroesophageal adenocarcinoma (GEA). These designations mean zanidatamab is eligible for Accelerated Approval, Priority Review and Rolling Review, as well as intensive FDA guidance on an efficient drug development program. Zanidatamab has also received Orphan Drug designations for the treatment of biliary tract, gastric and ovarian cancers, as well as Orphan Drug designation for the treatment of gastric cancer from the European Medicines Agency.

About Zymeworks Inc.

Zymeworks is a clinical-stage biopharmaceutical company dedicated to the development of next-generation multifunctional biotherapeutics. Zymeworks’ suite of therapeutic platforms and its fully integrated drug development engine enable precise engineering of highly differentiated product candidates. Zymeworks’ lead clinical candidate, zanidatamab, is a novel Azymetric™ bispecific antibody which has been granted Breakthrough Therapy designation by the FDA and is currently in a registration-enabling clinical trial for refractory HER2-amplified biliary tract cancer as well as several Phase 2 clinical trials for HER2-positive gastroesophageal and breast cancers. Zymeworks’ second clinical candidate, ZW49, is a bispecific antibody-drug conjugate currently in Phase 1 clinical development and combines the unique design and antibody framework of zanidatamab with Zymeworks’ proprietary ZymeLink™ linker-cytotoxin. Zymeworks is also advancing a deep preclinical pipeline in oncology (including immuno-oncology agents) and other therapeutic areas. In addition, its therapeutic platforms are being leveraged through strategic partnerships with nine biopharmaceutical companies. For more information, visit www.zymeworks.com and follow us @ZymeworksInc on Twitter.

Cautionary Note Regarding Forward-Looking Statements

This press release includes “forward-looking statements” within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and “forward-looking information” within the meaning of Canadian securities laws, or collectively, forward-looking statements. Forward-looking statements in this press release include, but are not limited to, statements that relate to Zymeworks’ clinical and preclinical development of its product candidates, the potential therapeutic effects of zanidatamab, and other information that is not historical information. When used herein, words such as “will”, “may”, and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon Zymeworks’ current expectations and various assumptions. Zymeworks believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. Zymeworks may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various factors, including, without limitation, market conditions and the factors described under “Risk Factors” in Zymeworks’ Quarterly Report on Form 10-Q for its quarter ended September 30, 2020 (a copy of which may be obtained at www.sec.gov and www.sedar.com). Consequently, forward-looking statements should be regarded solely as Zymeworks’ current plans, estimates and beliefs. Investors should not place undue reliance on

forward-looking statements. Zymeworks cannot guarantee future results, events, levels of activity, performance, or achievements. Zymeworks does not undertake and specifically declines any obligation to update, republish, or revise any forward-looking statements to reflect new information, future events or circumstances or to reflect the occurrences of unanticipated events, except as may be required by law.

Contacts:

Investor Inquiries:

Ryan Dercho, Ph.D.

(604) 678-1388

ir@zymeworks.com

Tiffany Tolmie

(604) 678-1388

ir@zymeworks.com

Media Inquiries:

Mary Klem

(604) 678-1388

media@zymeworks.com

EX-101.SCH 3 zyme-20201210.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 zyme-20201210_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Country Entity Address, Country Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 zyme-20201210_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g75372g1210125844670.jpg GRAPHIC begin 644 g75372g1210125844670.jpg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end XML 7 d75372d8k_htm.xml IDEA: XBRL DOCUMENT 0001403752 2020-12-10 2020-12-10 false 0001403752 8-K 2020-12-10 Zymeworks Inc. A1 001-38068 98-1398788 Suite 540 1385 West 8th Avenue Vancouver BC CA V6H 3V9 (604) 678-1388 false false false false Common Shares, no par value per share ZYME NYSE false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Document and Entity Information
Dec. 10, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001403752
Document Type 8-K
Document Period End Date Dec. 10, 2020
Entity Registrant Name Zymeworks Inc.
Entity Incorporation State Country Code A1
Entity File Number 001-38068
Entity Tax Identification Number 98-1398788
Entity Address, Address Line One Suite 540
Entity Address, Address Line Two 1385 West 8th Avenue
Entity Address, City or Town Vancouver
Entity Address, State or Province BC
Entity Address, Country CA
Entity Address, Postal Zip Code V6H 3V9
City Area Code (604)
Local Phone Number 678-1388
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Shares, no par value per share
Trading Symbol ZYME
Security Exchange Name NYSE
Entity Emerging Growth Company false
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d75372d8k.htm d75372dex991.htm zyme-20201210.xsd zyme-20201210_lab.xml zyme-20201210_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d75372d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d75372d8k.htm" ] }, "labelLink": { "local": [ "zyme-20201210_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "zyme-20201210_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "zyme-20201210.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://xbrl.sec.gov/sic/2011/sic-2011-01-31.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "zyme", "nsuri": "http://imetrix.edgar-online.com/20201210", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d75372d8k.htm", "contextRef": "duration_2020-12-10_to_2020-12-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d75372d8k.htm", "contextRef": "duration_2020-12-10_to_2020-12-10", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCountry": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "ISO 3166-1 alpha-2 country code.", "label": "Entity Address, Country", "terseLabel": "Entity Address, Country" } } }, "localname": "EntityAddressCountry", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "countryCodeItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://imetrix.edgar-online.com//20201210/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001193125-20-314855-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-20-314855-xbrl.zip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end